Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 21, 2021Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, ("Menarini"), a privately-held, leading...
-
Dec 17, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner, Antengene Corporation (Antengene), has...
-
Dec 11, 2021-- 40% of Patients with Myelofibrosis Who Received at Least 24 Weeks of Selinexor Treatment Achieved a Response, Defined as ≥35% Spleen Volume Reduction --
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting updated data from the...
-
Dec 6, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Peter K Honig, MD, MPH, to the Board of...
-
Dec 6, 2021
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in a new Phase 2 study...
-
Dec 2, 2021- Top-Line Study Results Expected by End of 2021 or Early 2022 -
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the completion of patient recruitment in the Phase 3...
-
Dec 1, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of...
-
Dec 1, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a virtual Investor Day on Wednesday, December...
-
Nov 11, 2021
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer...
-
Nov 4, 2021-- 33% of Patients Who Received at Least 24 Weeks of Selinexor Treatment Achieved a Response, Defined as ≥35% Spleen Volume Reduction (SVR) --
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a Phase 2 study...
-
Nov 3, 2021-- Third Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $26.7 Million, Up 32% Sequential Quarter-Over-Quarter and 25% Year-Over-Year --
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2021...
-
Nov 1, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of...
-
Oct 27, 2021-- Conference Call Scheduled for Wednesday, November 3, 2021, at 8:30 a.m. ET --
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2021 financial results...
-
Oct 21, 2021
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an...
-
Oct 1, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of...
-
Sep 7, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive...
-
Sep 1, 2021
Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of Eleonora Goldberg,...
-
Aug 5, 2021-- Achieved Second Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First Half of 2020 --
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter...
-
Aug 3, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive...
-
Aug 2, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of...
-
Jul 29, 2021-- Conference Call Scheduled for Thursday, August 5, 2021, at 8:30 a.m. ET --
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report second quarter 2021 financial results...
-
Jul 28, 2021
Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored...
-
Jul 1, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of Ms. Sohanya Cheng,...
-
Jun 24, 2021− Investment Expected to Extend Karyopharm's Cash Runway into the Middle of 2023 -
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities...
-
Jun 9, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual...